Fluconazole exposure during mechanical circulatory support (MCS) device insertion
In 10 patients undergoing MCS device insertion, fluconazole 200 to 400 mg IV achieved median plasma levels of between 3 and 4 mg/L throughout the surgical procedure but may not adequately cover for C. glabrata.
Authors
- Hans G. Schneider (ORCID: https://orcid.org/0000-0002-6048-8744)
- David M. Kaye (ORCID: https://orcid.org/0000-0003-4058-0372)
- Trisha Peel (ORCID: https://orcid.org/0000-0003-2370-2438)
- Andrew Alexander Udy (ORCID: https://orcid.org/0000-0002-6284-2022)
- Silvana Marasco (ORCID: https://orcid.org/0000-0001-7826-0986)
- Katherine Morton (ORCID: https://orcid.org/0000-0002-6674-0314)
- Iain J. Abbott (ORCID: https://orcid.org/0000-0001-6590-6127)
- Kelly A. Cairns (ORCID: https://orcid.org/0000-0002-9969-3972)
- Jeffrey D. Pope (ORCID: https://orcid.org/0000-0002-1993-6779)
- VICTOR T. WARNER
- David Daly
- Michael Dooley
- Anna Coldham
Institutions
- College of Intensive Care Medicine (AU)
- The Alfred Hospital (AU)
- Lismore Base Hospital (AU)
- Australian and New Zealand Intensive Care Society (AU)
- Monash Alfred Psychiatry Research centre (AU)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- International Journal of Antimicrobial Agents
- Published
- 2025-10-19
- DOI
- https://doi.org/10.1016/j.ijantimicag.2025.107647
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00